Latest update on US FDA BLA for Novavax's COVID-19 vaccine

23 April 2025 - We believe that our biologics license application is approvable based on conversations with the US FDA, ...

Read more →

Arcturus Therapeutics receives US FDA fast track designation for the STARR mRNA vaccine candidate ARCT-2304 for pandemic influenza A virus H5N1

10 April 2025 - Arcturus Therapeutics today announced that the US FDA has granted fast track designation for the self-amplifying mRNA ...

Read more →

Update on US FDA BLA for Novavax’s COVID-19 vaccine

2 April 2025 - Novavax can confirm that 1 April 2025, was the US FDA’s Prescription Drug User Fee Act date ...

Read more →

Bavarian Nordic receives US FDA approval of freeze dried smallpox and mpox vaccine

31 March 2025 - Bavarian Nordic today announced that the US FDA has approved the freeze dried formulation of Jynneos (smallpox ...

Read more →

Chlamydia vaccine candidate granted fast track designation by the US FDA

26 March 2025 - The US FDA has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of ...

Read more →

Bavarian Nordic receives US FDA approval of chikungunya vaccine for persons aged 12 and older

14 February 2025 - On track for commercial launch in the US in the first half of 2025. ...

Read more →

Penmenvy, GSK’s 5 in 1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY

15 February 2025 - Broad serogroup coverage in one vaccine reduces injections to help improve vaccination rates and help protect ...

Read more →

GSK’s Shingrix new pre-filled syringe presentation accepted for review by US FDA

10 January 2025 - An FDA decision on the application is expected by 20 June 2025. ...

Read more →

LimmaTech awarded FDA fast track designation for vaccine candidate against Staphylococcus aureus

19 December 2024 - LimmaTech Biologics announced today that the US FDA has granted fast track designation to LimmaTech’s multivalent ...

Read more →

Two combination vaccine candidates for prevention of influenza and COVID-19 granted fast track designation in the US

11 December 2024 - Two Phase 1/2 clinical studies are ongoing to evaluate the safety profile and immune response induced by ...

Read more →

Valneva submits label extension application for its Chikungunya vaccine, Ixchiq, to the US FDA

26 November 2024 - To potentially include adolescents and antibody persistence up to two years. ...

Read more →

US FDA approves Pfizer’s RSV vaccine Abrysvo for adults aged 18 to 59 at increased risk for disease

22 October 2024 - Approval based on data from pivotal Phase 3 trial in adults at increased risk of lower ...

Read more →

Valneva and LimmaTech awarded FDA fast track designation for tetravalent Shigella vaccine candidate S4V

16 October 2024 - Valneva and LimmaTech Biologics announced today that the US FDA has granted fast track designation to ...

Read more →

The FDA approved a self-administered nasal spray for the flu. Here’s how it compares to the traditional flu shot.

6 October 2024 - The US FDA recently approved FluMist as a self or caregiver-administered nasal spray flu vaccine to prevent ...

Read more →

FDA approves nasal spray influenza vaccine for self or caregiver administration

20 September 2024 - First influenza vaccine that does not need to be administered by a health care provider. ...

Read more →